MacroGenics (MGNX) Competitors $1.44 +0.06 (+4.35%) As of 07/3/2025 03:37 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MGNX vs. BNTC, AVIR, IVA, AARD, OCGN, GOSS, ALT, GLUE, RNAC, and TKNOShould you be buying MacroGenics stock or one of its competitors? The main competitors of MacroGenics include Benitec Biopharma (BNTC), Atea Pharmaceuticals (AVIR), Inventiva (IVA), Aardvark Therapeutics (AARD), Ocugen (OCGN), Gossamer Bio (GOSS), Altimmune (ALT), Monte Rosa Therapeutics (GLUE), Cartesian Therapeutics (RNAC), and Alpha Teknova (TKNO). These companies are all part of the "pharmaceutical products" industry. MacroGenics vs. Its Competitors Benitec Biopharma Atea Pharmaceuticals Inventiva Aardvark Therapeutics Ocugen Gossamer Bio Altimmune Monte Rosa Therapeutics Cartesian Therapeutics Alpha Teknova Benitec Biopharma (NASDAQ:BNTC) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment. Which has stronger valuation & earnings, BNTC or MGNX? Benitec Biopharma has higher earnings, but lower revenue than MacroGenics. Benitec Biopharma is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBenitec BiopharmaN/AN/A-$21.75M-$1.51-8.70MacroGenics$149.96M0.61-$66.97M-$0.89-1.62 Is BNTC or MGNX more profitable? Benitec Biopharma has a net margin of 0.00% compared to MacroGenics' net margin of -36.23%. Benitec Biopharma's return on equity of -38.26% beat MacroGenics' return on equity.Company Net Margins Return on Equity Return on Assets Benitec BiopharmaN/A -38.26% -35.71% MacroGenics -36.23%-59.84%-23.45% Does the media prefer BNTC or MGNX? In the previous week, MacroGenics had 1 more articles in the media than Benitec Biopharma. MarketBeat recorded 3 mentions for MacroGenics and 2 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 0.58 beat MacroGenics' score of 0.23 indicating that Benitec Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Benitec Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MacroGenics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals hold more shares of BNTC or MGNX? 52.2% of Benitec Biopharma shares are owned by institutional investors. Comparatively, 96.9% of MacroGenics shares are owned by institutional investors. 1.3% of Benitec Biopharma shares are owned by insiders. Comparatively, 13.0% of MacroGenics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more volatility and risk, BNTC or MGNX? Benitec Biopharma has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500. Comparatively, MacroGenics has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500. Do analysts prefer BNTC or MGNX? Benitec Biopharma currently has a consensus target price of $23.83, suggesting a potential upside of 81.38%. MacroGenics has a consensus target price of $5.71, suggesting a potential upside of 296.83%. Given MacroGenics' higher probable upside, analysts clearly believe MacroGenics is more favorable than Benitec Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Benitec Biopharma 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22MacroGenics 0 Sell rating(s) 7 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.40 SummaryMacroGenics beats Benitec Biopharma on 9 of the 16 factors compared between the two stocks. Get MacroGenics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGNX vs. The Competition Export to ExcelMetricMacroGenicsMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$92.11M$10.52B$5.55B$9.04BDividend YieldN/A2.07%5.22%4.00%P/E Ratio-1.6217.0327.6420.24Price / Sales0.6129.54417.15117.30Price / CashN/A22.9936.8958.10Price / Book0.783.668.035.67Net Income-$66.97M$235.40M$3.18B$249.21M7 Day Performance21.01%2.15%2.93%3.28%1 Month Performance-19.10%1.07%1.72%3.95%1 Year Performance-65.71%-10.17%34.39%20.98% MacroGenics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGNXMacroGenics4.1248 of 5 stars$1.44+4.3%$5.71+296.8%-65.7%$92.11M$149.96M-1.62430Gap UpBNTCBenitec Biopharma2.0159 of 5 stars$11.70+3.1%$23.83+103.7%+41.4%$297.94M$80K-7.7520High Trading VolumeAVIRAtea Pharmaceuticals2.3686 of 5 stars$3.60+4.3%$6.00+66.7%+12.9%$295.25MN/A-2.1870High Trading VolumeIVAInventiva2.7621 of 5 stars$3.19+4.6%$10.40+226.0%+3.7%$291.77M$9.95M0.00100News CoverageGap UpAARDAardvark TherapeuticsN/A$13.52+1.0%$33.00+144.1%N/A$290.51MN/A0.0018News CoverageAnalyst RevisionGap UpOCGNOcugen0.9834 of 5 stars$0.97-1.4%$6.00+518.3%-43.5%$287.39M$4.05M-5.1180High Trading VolumeGOSSGossamer Bio3.662 of 5 stars$1.23-1.6%$7.33+496.2%+13.4%$284.13M$114.70M-5.35180ALTAltimmune2.2318 of 5 stars$3.87+10.6%$19.00+391.0%-28.1%$283.87M$20K-3.0750High Trading VolumeGLUEMonte Rosa Therapeutics1.349 of 5 stars$4.51-2.0%$15.33+240.0%+38.6%$282.95M$75.62M56.3890News CoverageRNACCartesian Therapeutics1.4416 of 5 stars$10.39-2.7%$41.25+297.0%-34.1%$277.19M$38.91M-0.2064TKNOAlpha Teknova3.0225 of 5 stars$4.91-3.9%$8.50+73.1%+335.0%$273.08M$37.74M-10.23240 Related Companies and Tools Related Companies Benitec Biopharma Alternatives Atea Pharmaceuticals Alternatives Inventiva Alternatives Aardvark Therapeutics Alternatives Ocugen Alternatives Gossamer Bio Alternatives Altimmune Alternatives Monte Rosa Therapeutics Alternatives Cartesian Therapeutics Alternatives Alpha Teknova Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGNX) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored140% Yields From Stocks Like Tesla? Here's How (July 4th Special)Imagine getting a 140% dividend from your investments. Even better? It works with big names like Tesla, ...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MacroGenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MacroGenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MGNX Stock Alerts